

EQA round: VVV1/24 - Maternal Diagnostic Screening (Triple Test)

Deadline: 19.4.2024

Setup: groups - R (manufacturer of kit); Slovakia; minimal size of the groups n = 5

RoM = robust average	AV = assigned value	D _{max} = acceptable difference
SD = standard deviation	CVPG = consensus of the participants' groups	LL = lower limit
CV = coefficient of variation	U _{AV} = expanded uncertainty of the assigned value (k = 2)	UL = upper limit
N _{tot} = total number of the results		N _{eva} = number of the results assessed
N _{out} = number of the results removed before calculation		N _{suc} = number of successful results
		S _{rel} = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability					N _{eva}	N _{suc}	S _{rel} [%]
							AV	U _{AV}	D _{max}	LL	UL			
Set 1														
(238) free β-hCG	[U/L]				10							10	10	100
Sample A1		39,8	1,2	3	10							10	10	100
(60) Roche		39,7	1	2,6	9	0	CVPG	39,5	0,64	15%	33,5	45,5	9	
Other					1	0							1	
							1x 24							
Sample B1		136	4,8	3,5	10							10	10	100
(60) Roche		136	4,4	3,3	9	0	CVPG	135	1,9	15%	114	156	9	
Other					1	0							1	
							1x 24							
(239) PAPP-A	[U/L]				13							13	13	100
Sample A1		1,17	0,034	2,9	13							13	13	100
(60) Roche		1,17	0,036	3,1	11	0	CVPG	1,18	0,021	15%	1	1,36	11	
Other					2	0							2	
							2x 24							
Sample B1		6,93	0,44	6,3	13							13	13	100
(60) Roche		6,91	0,46	6,7	11	0	CVPG	6,94	0,14	15%	5,89	7,99	11	
Other					2	0							2	
							2x 24							
Set 2														
(370) AFP	[μg/L]				13							10	10	100
Sample A2		33,9	2,1	6,1	13							10	10	100
(60) Roche		34,4	1,2	3,6	6	0	CVPG	35,3	1,1	20%	28,2	42,4	6	
Other					7	0							4	
							1x 1, 4x 12, 1x 162, 1x 179							
Sample B2		147	11	7,2	13							10	10	100
(60) Roche		155	6,2	4	6	0	CVPG	159	5	20%	127	191	6	
Other					7	0							4	
							1x 1, 4x 12, 1x 162, 1x 179							
(373) hCG	[kU/L]				13							9	7	78
Sample A2		31,5	7,1	23	13							9	7	78
(60) Roche		28,8	1,6	5,6	6	0	CVPG	28,3	1	18%	23,2	33,4	6	
Other					7	0							3	
							1x 1, 3x 12, 1x 29, 1x 36, 1x 179							
Sample B2		38,2	8,7	23	13							9	8	89
(60) Roche		35,4	2,7	7,5	6	0	CVPG	34,1	1,3	18%	27,9	40,3	6	
Other					7	0							3	
							1x 1, 3x 12, 1x 29, 1x 36, 1x 179							
(375) Estriol unconjug.	[nmol/L]				13							13	13	100
Sample A2		2,03	1,1	53	13							13	13	100
(12) Beckman Coulter		3,27	0,3	9,1	5	0	CVPG	2,92	0,21	33%	1,95	3,89	5	
(29) Siemens (Immulite)		1,36	0,19	14	8	0	CVPG	1,31	0,13	33%	0,877	1,75	8	
Sample B2		8,62	2,6	30	13							13	13	100
(12) Beckman Coulter		11,3	0,63	5,6	5	0	CVPG	10,5	0,63	33%	7,03	14	5	
(29) Siemens (Immulite)		6,89	0,54	7,9	8	0	CVPG	6,87	0,4	33%	4,6	9,14	8	
1. trimester														
(240) free β-hCG (MoM)	[MoM]				8							8	8	100
Mother X1		0,81	0,059	7,3	8							8	8	100
(60) Roche		0,81	0,059	7,3	7	0	CVPG	0,824	0,03	33%	0,552	1,1	7	
Other					1	0							1	
							1x 24							
Mother Y1		3,9	0,59	15	8							8	8	100
(60) Roche		3,9	0,59	15	7	0	CVPG	3,87	0,19	33%	2,59	5,15	7	
Other					1	0							1	
							1x 24							
(241) PAPP-A (MoM)	[MoM]				12							12	12	100
Mother X1		0,63	0,053	8,4	12							12	12	100
(60) Roche		0,635	0,054	8,5	10	0	CVPG	0,612	0,031	33%	0,41	0,814	10	
Other					2	0							2	
							2x 24							
Mother Y1		1,95	0,24	12	12							12	12	100
(60) Roche		1,99	0,2	9,9	10	0	CVPG	1,96	0,1	33%	1,31	2,61	10	
Other					2	0							2	
							2x 24							

EQA round: VVV1/24 - Maternal Diagnostic Screening (Triple Test)

Deadline: 19.4.2024

Setup: groups - R (manufacturer of kit); Slovakia; minimal size of the groups n = 5

Test Sample Group	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability					N _{eva}	N _{suc}	S _{rel} [%]
							AV	U _{AV}	D _{max}	LL	UL			
2. trimester														
(380) AFP (MoM)	[MoM]				13							10	9	90
Mother X2		0,967	0,12	12	13							10	9	90
(60) Roche		0,935	0,13	13	6	0	CVPG	0,924	0,047	23%	0,711	1,14	6	
Other					7	0						4		
								1x 1, 4x 12, 1x 162, 1x 179						
Mother Y2		4,15	0,3	7,3	13							10	9	90
(60) Roche		4,05	0,46	11	6	0	CVPG	4,16	0,23	23%	3,2	5,12	6	
Other					7	0						4		
								1x 1, 4x 12, 1x 162, 1x 179						
(382) hCG (MoM)	[MoM]				13							9	9	100
Mother X2		0,956	0,16	16	13							9	9	100
(60) Roche		0,895	0,082	9,1	6	0	CVPG	0,97	0,097	40%	0,582	1,36	6	
Other					7	0						3		
								1x 1, 3x 12, 1x 29, 1x 36, 1x 179						
Mother Y2		1,15	0,18	16	13							9	9	100
(60) Roche		1,12	0,15	13	6	0	CVPG	1,18	0,11	40%	0,708	1,66	6	
Other					7	0						3		
								1x 1, 3x 12, 1x 29, 1x 36, 1x 179						
(384) Estriol unconjug. (MoM)	[MoM]				13							13	12	92
Mother X2		0,903	0,17	19	13							13	12	92
(12) Beckman Coulter		0,91	0,12	13	5	0	CVPG	0,915	0,068	40%	0,549	1,29	5	
(29) Siemens (Immulin)		0,92	0,22	24	8	0	CVPG	0,86	0,11	40%	0,516	1,21	8	
Mother Y2		4,32	1,2	27	13							13	12	92
(12) Beckman Coulter		3,42	0,2	5,9	5	0	CVPG	3,35	0,19	40%	2,01	4,69	5	
(29) Siemens (Immulin)		4,75	1,2	25	8	0	CVPG	4,54	0,65	40%	2,72	6,36	8	